Search

Your search keyword '"Ivana Lagreca"' showing total 10 results
Start Over Author "Ivana Lagreca" Topic business
10 results on '"Ivana Lagreca"'

1. Epidemiology and clinical outcomes of latent tuberculosis infection in adults affected with acute leukemia or aplastic anemia: a retrospective single-center study

Author

Cristina Mussini, Patrizia Barozzi, Andrea Gilioli, Patrizia Comoli, Ivana Lagreca, Valeria Pioli, Rossana Maffei, Elisabetta Colaci, Francesca Bettelli, Vincenzo Nasillo, Daniela Vallerini, Hillary Catellani, Franco Narni, Erica Franceschini, Davide Giusti, Fabio Forghieri, Roberto Marasca, Monica Morselli, Mario Luppi, Leonardo Potenza, Roberto D'Amico, Silvia Iotti, Rachele Giubbolini, Corrado Colasante, Laura Galassi, and Federico Banchelli

Subjects
Adult, Myeloid, Pediatrics, medicine.medical_specialty, Adolescent, medicine.medical_treatment, Antitubercular Agents, Comorbidity, Hematopoietic stem cell transplantation, Acute, Single Center, Young Adult, Latent Tuberculosis, Epidemiology, Isoniazid, 80 and over, medicine, Humans, Latent tuberculosis infection, Aplastic anemia, Aged, Febrile Neutropenia, Retrospective Studies, Aged, 80 and over, Acute leukemia, Leukemia, Latent tuberculosis, business.industry, Aplastic, Hematopoietic Stem Cell Transplantation, Anemia, Aplastic, Active tuberculosis disease, Anemia, Retrospective cohort study, Hematology, General Medicine, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Combined Modality Therapy, Leukemia, Myeloid, Acute, BCG Vaccine, Interferon-gamma Release Tests, business, BCG vaccine
Published
2020
Full Text
View/download PDF

2. Pre-existing cytopenia heralding de novo acute myeloid leukemia: Uncommon presentation of NPM1-mutated AML in a single-center study

Author

Ivana Lagreca, Vincenzo Nasillo, Francesca Donatelli, Andrea Gilioli, Elisabetta Colaci, Tommaso Trenti, Davide Giusti, Maria Nurmi Del Rosso, Rossana Maffei, Laura Galassi, Luca Roncati, Rossella Manfredini, Roberto Marasca, Mario Luppi, E. Barbieri, Elena Tenedini, Fabio Forghieri, Corrado Colasante, Enrico Tagliafico, Giovanni Riva, Silvia Martinelli, Hillary Catellani, Patrizia Comoli, Stefano Pozzi, Ambra Paolini, Francesca Bettelli, Leonardo Potenza, Monica Morselli, Patrizia Barozzi, Valeria Pioli, and Beatrice Lusenti

Subjects
Adult, Myeloid, Male, Oncology, Cancer Research, medicine.medical_specialty, NPM1, Neutropenia, Pancytopenia, Acute, Single Center, Text mining, Internal medicine, medicine, Humans, Aged, Retrospective Studies, Cytopenia, Anemia, Female, Follow-Up Studies, Leukemia, Myeloid, Acute, Middle Aged, Nucleophosmin, Prognosis, Thrombocytopenia, Leukemia, business.industry, De novo acute, Myeloid leukemia, Hematology, medicine.disease, Presentation (obstetrics), business
Published
2021
Full Text
View/download PDF

3. All‐trans retinoic acid (ATRA) in non‐promyelocytic acute myeloid leukemia (AML): results of combination of ATRA with low‐dose Ara‐C in three elderly patients with NPM1 ‐mutated AML unfit for intensive chemotherapy and review of the literature

Author

Elisabetta Colaci, Ivana Lagreca, Brunangelo Falini, Giovanni Riva, Maria Paola Martelli, Roberto Marasca, Leonardo Potenza, Franco Narni, Chiara Quadrelli, Sergio Amadori, Ambra Paolini, Adriano Venditti, Patrizia Barozzi, Fabio Forghieri, Sara Bigliardi, Mario Luppi, Francesco Lo Coco, Patrizia Zucchini, Daniela Vallerini, and Monica Morselli

Subjects
0301 basic medicine, Oncology, NPM1, medicine.medical_specialty, business.industry, Low dose, All trans, Retinoic acid, Myeloid leukemia, General Medicine, Intensive chemotherapy, Pharmacology, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, chemistry, hemic and lymphatic diseases, 030220 oncology & carcinogenesis, Internal medicine, Flt3 mutation, Medicine, business
Abstract

Based upon the clinical behavior of three patients, we suggest that the combination of low-dose Ara-C and all-trans retinoic acid may potentially be effective in some elderly patients, unfit for intensive chemotherapy, affected with NPM1-mutated acute myeloid leukemia without FLT3 mutations, warranting perspective clinical studies in these selected patients.

Published
2016
Full Text
View/download PDF

4. Effectiveness of originator (Neupogen) and biosimilar (Zarzio) filgrastim in autologous peripheral blood stem cell mobilization in adults with acute myeloid leukemia: a single-center retrospective study

Author

Vincenzo Nasillo, Elisabetta Lugli, Valeria Pioli, Laura Arletti, Paola Bresciani, Monica Maccaferri, Valeria Coluccio, Elisabetta Colaci, Mario Luppi, Andrea Messerotti, G. Ceccherelli, Maria Teresa Mariano, Angela Cuoghi, Ambra Paolini, Ivana Lagreca, Franco Narni, Chiara Quadrelli, Valeria Fantuzzi, Daniele Campioli, Giovanni Riva, Andrea Gilioli, Patrizia Barozzi, Leonardo Potenza, Roberto Marasca, Patrizia Comoli, Fabio Forghieri, Patrizia Zucchini, Tommaso Trenti, Daniela Vallerini, and Monica Morselli

Subjects
Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Filgrastim, 030204 cardiovascular system & hematology, acute myeloid leukemia, Single Center, Biosimilars, filgrastim, autologous peripheral blood stem cell mobilization, acute myeloid leukemia, Transplantation, Autologous, 03 medical and health sciences, Young Adult, 0302 clinical medicine, Internal medicine, Hematologic Agents, medicine, Humans, Biosimilar Pharmaceuticals, Retrospective Studies, Biosimilars, Peripheral Blood Stem Cell Transplantation, business.industry, Myeloid leukemia, Biosimilar, Retrospective cohort study, Hematology, Middle Aged, medicine.disease, Hematopoietic Stem Cell Mobilization, Transplantation, Leukemia, autologous peripheral blood stem cell mobilization, Treatment Outcome, Leukemia, Myeloid, 030220 oncology & carcinogenesis, Pharmacodynamics, Acute Disease, Peripheral Blood Stem Cells, Female, business, filgrastim, medicine.drug
Abstract

Biosimilars of filgrastim have shown to be comparable to the originator (Neupogen®, Amgen Inc., CA) in terms of pharmacodynamic response in healthy subjects, as well as in overall efficacy and safe...

Published
2017

5. PS1128 FUNGI INFECTION VERSUS IBRUTINIB TREATMENT: ROLE OF NURSE-LIKE CELLS DURING ASPERGILLUS FUMIGATUS INFECTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS

Author

S. Fiorcari, Ivana Lagreca, Rossana Maffei, Silvia Martinelli, R. Marasca, D. Vallerini, P. Zucchini, M. Luppi, S. Benatti, Patrizia Barozzi, and Leonardo Potenza

Subjects
chemistry.chemical_compound, biology, chemistry, business.industry, Chronic lymphocytic leukemia, Ibrutinib, Immunology, medicine, Hematology, biology.organism_classification, medicine.disease, business, Aspergillus fumigatus
Published
2019
Full Text
View/download PDF

6. PS1274 EPIDEMIOLOGY AND MANAGEMENT OF LATENT TUBERCULOSIS INFECTION IN ADULT PATIENTS WITH ACUTE LEUKEMIA OR APLASTIC ANEMIA: A RETROSPECTIVE MONOCENTER STUDY

Author

P. Barozzi, M. Luppi, F. Forghieri, M. Celli, A. Messerotti, C. Mussini, Ivana Lagreca, E. Colaci, L. Potenza, A. Gilioli, S. Iotti, F. Narni, D. Giusti, M. Codeluppi, D. Vallerini, L. Arletti, H. Catellani, Erica Franceschini, V. pioli, V. Nasillo, Monica Morselli, Rossana Maffei, F. Bettelli, Giovanni Riva, A. Paolini, C. Colasante, L. Galassi, R. Marasca, and F. Donatelli

Subjects
Pediatrics, medicine.medical_specialty, Acute leukemia, Adult patients, Latent tuberculosis, business.industry, Epidemiology, medicine, Hematology, Aplastic anemia, medicine.disease, business
Published
2019
Full Text
View/download PDF

7. BCR-ABL-specific T-cell therapy in Ph+ ALL patients on tyrosine-kinase inhibitors

Author

Robin Foà, Marco Zecca, Giuseppe Quartuccio, Ambra Paolini, Laura Rubert, Franco Narni, Lorenzo Iughetti, Ivana Lagreca, Patrizia Comoli, Leonardo Potenza, Mario Luppi, Fabio Forghieri, Patrizia Barozzi, Tommaso Trenti, Sabrina Basso, Daniela Vallerini, Monica Morselli, Ilaria Guido, Antonella Gurrado, Roberto Marasca, Elisabetta Colaci, Angela Cuoghi, Antonio Cuneo, Paola Bresciani, and Giovanni Riva

Subjects
0301 basic medicine, Adult, Male, medicine.medical_specialty, T cell, Immunology, Fusion Proteins, bcr-abl, Priming (immunology), Biochemistry, NO, 03 medical and health sciences, In vivo, Inside BLOOD Commentary, Internal medicine, hemic and lymphatic diseases, medicine, Cytotoxic T cell, Humans, Protein Kinase Inhibitors, Cells, Cultured, Hematology, business.industry, leukemia, Cell Biology, Middle Aged, Precursor Cell Lymphoblastic Leukemia-Lymphoma, medicine.disease, Adoptive Transfer, Leukemia, 030104 developmental biology, medicine.anatomical_structure, Female, Bone marrow, business, Ex vivo, T-Lymphocytes, Cytotoxic
Abstract

Although the emergence of bone marrow (BM)-resident p190BCR-ABL-specific T lymphocytes has been correlated with hematologic and cytogenetic remissions in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) undergoing maintenance tyrosine-kinase inhibitor treatment, little is known about the possibility of culturing these cells ex vivo and using them in T-cell therapy strategies. We investigated the feasibility of expanding/priming p190BCR-ABL-specific T cells in vitro by stimulation with dendritic cells pulsed with p190BCR-ABL peptides derived from the BCR-ABL junctional region and alternative splicing, and of adoptively administering them to patients with relapsed disease. We report on the feasibility of producing clinical-grade BCR-ABL-specific cytotoxic T lymphocytes (CTLs), endowed with antileukemia activity, from Ph+ ALL patients and healthy donors. We treated 3 patients with Ph+ ALL with autologous or allogeneic p190BCR-ABL-specific CTLs. No postinfusion toxicity was observed, except for a grade II skin graft-versus-host disease in the patient treated for hematologic relapse. All patients achieved a molecular or hematologic complete remission (CR) after T-cell therapy, upon emergence of p190BCR-ABL-specific T cells in the BM. Our results show that p190BCR-ABL-specific CTLs are capable of controlling treatment-refractory Ph+ ALL in vivo, and support the development of adoptive immunotherapeutic approaches with BCR-ABL CTLs in Ph+ ALL.

Published
2017

8. Epidemiology and clinical outcome of lower respiratory tract infections by respiratory syncytial virus or parainfluenza virus type 3 in adults receiving treatment for either acute leukemia or severe aplastic anemia: a retrospective single center study

Author

Elisabetta Lugli, Elisabetta Colaci, Monica Morselli, Francesco Soci, Vincenzo Nasillo, Valeria Pioli, Ivana Lagreca, Fabio Forghieri, Roberto Marasca, Valeria Coluccio, Leonardo Potenza, Giovanni Riva, Sara Bigliardi, Patrizia Barozzi, Mauro Codeluppi, Daniela Vallerini, Erica Franceschini, Cristina Mussini, Chiara Quadrelli, Laura Arletti, Ambra Paolini, Mario Luppi, Andrea Gilioli, Franco Narni, Valeria Fantuzzi, Monica Maccaferri, and Andrea Messerotti

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, STEM-CELL TRANSPLANTATION, RECIPIENTS, Respiratory Syncytial Virus Infections, Single Center, Respirovirus Infections, Virus, Young Adult, Internal medicine, Epidemiology, medicine, Humans, Respiratory system, Aplastic anemia, Respiratory Tract Infections, Aged, Retrospective Studies, Aged, 80 and over, Acute leukemia, Leukemia, Hematology, Respiratory tract infections, business.industry, Anemia, Aplastic, General Medicine, Middle Aged, Prognosis, medicine.disease, Parainfluenza Virus 3, Human, Respiratory Syncytial Viruses, Treatment Outcome, Acute Disease, Immunology, Female, business
Published
2015
Full Text
View/download PDF

9. NPM1 mutations may reveal acute myeloid leukemia in cases otherwise morphologically diagnosed as myelodysplastic syndromes or myelodysplastic/myeloproliferative neoplasms

Author

Laura Arletti, Fabio Forghieri, Ivana Lagreca, Francesco Soci, Daniela Vallerini, Elisabetta Colaci, Cristina Mecucci, Emanuela Ottaviani, Valeria Fantuzzi, Valeria Pioli, Ambra Paolini, Vincenzo Nasillo, Patrizia Barozzi, Roberto Marasca, Patrizia Zucchini, Monica Morselli, Giovanna Leonardi, Franco Narni, Chiara Quadrelli, Goretta Bonacorsi, Valeria Coluccio, Laura Faglioni, Giorgia Corradini, Mario Luppi, Leonardo Potenza, Giovanni Riva, Giovanni Martinelli, Monica Maccaferri, Andrea Messerotti, Francesca Giacobbi, Brunangelo Falini, Sara Bigliardi, Forghieri, Fabio, Paolini, Ambra, Morselli, Monica, Bigliardi, Sara, Bonacorsi, Goretta, Leonardi, Giovanna, Coluccio, Valeria, Maccaferri, Monica, Fantuzzi, Valeria, Faglioni, Laura, Colaci, Elisabetta, Soci, Francesco, Nasillo, Vincenzo, Messerotti, Andrea, Arletti, Laura, Pioli, Valeria, Zucchini, Patrizia, Quadrelli, Chiara, Corradini, Giorgia, Giacobbi, Francesca, Vallerini, Daniela, Riva, Giovanni, Barozzi, Patrizia, Lagreca, Ivana, Marasca, Roberto, Narni, Franco, Mecucci, Cristina, Ottaviani, Emanuela, Martinelli, Giovanni, Falini, Brunangelo, Luppi, Mario, and Potenza, Leonardo

Subjects
medicine.medical_specialty, NPM1, Nucleophosmin, Cancer Research, Hematology, integumentary system, business.industry, NPM1 mutations, MDS, Myelodysplastic syndromes, De novo acute, Myeloid leukemia, Gene mutation, medicine.disease, NPM1 mutations, Oncology, hemic and lymphatic diseases, Internal medicine, MDS, medicine, Cancer research, business
Abstract

Nucleophosmin 1 (NPM1) gene mutations, resulting in aberrant cytoplasmic delocalization of NPM1 (NPMc+), are detected in about 30% of all de novo acute myeloid leukemia (AML) cases, and in 50–60% o...

Published
2015

10. Long-term molecular remission with persistence of BCR-ABL1-specific cytotoxic T cells following imatinib withdrawal in an elderly patient with Philadelphia-positive ALL

Author

Leonardo Potenza, Sabrina Basso, Ambra Paolini, Ilaria Iacobucci, Monica Morselli, Roberto Marasca, Patrizia Barozzi, Ivana Lagreca, Franco Narni, Fabio Forghieri, Valeria Fantuzzi, Mario Luppi, Daniela Vallerini, Monica Maccaferri, Andrea Messerotti, Eleonora Zanetti, Rossana Maffei, Giovanni Riva, Giovanni Martinelli, Patrizia Comoli, and Chiara Quadrelli

Subjects
Cytotoxic, T-Lymphocytes, bcr-abl, T cells, Philadelphia positive, Antineoplastic Agents, Piperazines, Persistence (computer science), Immunophenotyping, Bcr abl1, Medicine, Cytotoxic T cell, Humans, Elderly patient, Protein Kinase Inhibitors, Aged, business.industry, ALL, BCR-ABL1, Imatinib, MRD, Benzamides, Female, Fusion Proteins, bcr-abl, Immunologic Memory, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Pyrimidines, Remission Induction, T-Lymphocytes, Cytotoxic, Fusion Proteins, Hematology, Immunology, business, Immunologic memory, medicine.drug
Published
2014

Catalog

Books, media, physical & digital resources
See catalog results